Assessment of Coagulopathy Risk in Type 2 Diabetes Mellitus: A Retrospective Cross-Sectional Study in Thumbay Hospital, UAE

ORIGINAL ARTICLE
Fawzia Abdalla Alobeidli, Israa M. M. Abdalhadi, Hussam Ali Osman, Tagwa Yousif Elsayed Yousif, Ammar Abdelmola, Israa Omer Mahmoud Yousif, Muhammad Saboor, Khalid Abbas Owish Sukar, Noha Kamal Abdmomen, Ayman H. Alfeel

 
For citation: Alobeidli FA, Abdalhadi IMM, Osman HA, Yousif TYE, Abdelmola A, Yousif IOM, Saboor M, Sukar KAO, Abdmomen NK, Alfeel AH. Assessment of Coagulopathy Risk in Type 2 Diabetes Mellitus: A Retrospective Cross-Sectional Study in Thumbay Hospital, UAE. International Journal of Biomedicine. 2024;14(4):563-568. doi:10.21103/Article14(4)_OA4
 
Originally published December 5, 2024
 

Abstract: 

Background: Type 2 diabetes mellitus(T2DM) is associated with coagulation abnormalities and a higher risk for blood clots due to changes in the clotting factors and platelet function. This study aimed to assess blood clotting parameters in T2DM patients within a single research center in the UAE.
Methods and Results: This retrospective, cross-sectional study was conducted on 158 patients (112 men and 46 women) diagnosed with T2DM in Thumbay Hospital, Ajman, UAE. Blood samples were properly labeled and used for screening tests. The HbA1c and platelet tests were performed using the Beckman Coulter DxC 700 and DxH 900 analyzers. Coagulation profile tests, including D-dimer, activated partial thromboplastin time (APTT), and prothrombin time (PT), were performed using an ACL TOP 300 CTS analyzer.
All patients were divided into two groups. Group 1 included 68 patients with controlled diabetes (cT2DM), and Group 2 included 90 patients with uncontrolled diabetes (uT2DM). The assessment of the blood clotting parameters showed a lower level of INR in the uT2DM group than in the cT2DM group (1.06±0.10 and 1.53±1.13, respectively, P=0.0001). Platelet count, PT, APTT, and D-dimer levels did not differ significantly between the two groups. Men had a higher HbA1c than women (7.30±2.07% and 6.52±2.02%, respectively, P=0.0318), indicating poor diabetes control. Higher HbA1c in men was accompanied with a higher D-dimer level (409.1±44.4 ng/mL for men and 388.7±42.1 ng/mL for women, P=0.0086) and a lower level of INR (1.09±0.10 and 1.73±1.13, respectively, P=0.0001). Platelet count, PT and APTT levels did not differ significantly between male and female patients. Evaluation of the studied parameters, considering age groups, showed increased HbA1c with age (P=0.0018), indicating an increase in poor diabetes control. This was accompanied by a significant increase in the D-dimer levels in the age group above 45 (P=0.0000).The levels of other indicators did not differ significantly depending on the age group.
Conclusion: Patients with T2DM have a cumulative thrombotic risk. The prothrombotic state in T2DM is primarily mediated by hyperglycemia and insulin resistance. Good glycemic control (HbA1c<7.0%) in T2DM has reduced the risk of developing thrombotic complications.

Keywords: 
type 2 diabetes mellitus • thrombotic risk • platelet count • diabetes control
References: 
  1. Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019 Dec;576(7785):51-60. doi: 10.1038/s41586-019-1797-8. Epub 2019 Dec 4. PMID: 31802013.
  2. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 Aug 30;21(17):6275. doi: 10.3390/ijms21176275. PMID: 32872570; PMCID: PMC7503727.
  3. Ephraim RK, Awuku YA, Adu P, Ampomah LT, Adoba P, Panford S, Ninnoni JP, Agbodzakey H. High risk of coagulopathy among Type-2 Diabetes Mellitus clients at a municipal hospital in Ghana. Ghana Med J. 2017 Sep;51(3):101-107. doi: 10.4314/gmj.v51i3.2. PMID: 29622820; PMCID: PMC5870234.
  4. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother. 2020 Nov;131:110708. doi: 10.1016/j.biopha.2020.110708. Epub 2020 Sep 11. PMID: 32927252.
  5. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005 Apr 9-15;365(9467):1333-46. doi: 10.1016/S0140-6736(05)61032-X. PMID: 15823385.
  6. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999 Sep;104(6):787-94. doi: 10.1172/JCI7231. PMID: 10491414; PMCID: PMC408438.
  7. Reaven G. Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1754-9. doi: 10.1161/ATVBAHA.111.241885. PMID: 22815340.
  8. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011 Nov 2;14(5):575-85. doi: 10.1016/j.cmet.2011.07.015. PMID: 22055501; PMCID: PMC3217209.
  9. Davidson JA, Parkin CG. Is hyperglycemia a causal factor in cardiovascular disease? Does proving this relationship really matter? Yes. Diabetes Care. 2009 Nov;32 Suppl 2(Suppl 2):S331-3. doi: 10.2337/dc09-S333. PMID: 19875575; PMCID: PMC2811466.
  10. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014 May;10(5):293-302. doi: 10.1038/nrendo.2014.29. Epub 2014 Mar 25. PMID: 24663222.
  11. Goldberg R.B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab. 2009;
  12. Ebrahim H, Asrie F, Getaneh Z. Basic Coagulation Profiles and Platelet Parameters Among Adult Type 1 and Type 2 Diabetes Patients at Dessie Referral Hospital, Northeast Ethiopia: Comparative Cross-Sectional Study. J Blood Med. 2021 Jan 27;12:33-42. doi: 10.2147/JBM.S287136. PMID: 33536804; PMCID: PMC7850412.
  13. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002 May 15;287(19):2570-81. doi: 10.1001/jama.287.19.2570. PMID: 12020339.
  14. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med. 2004 Mar 8;116 Suppl 5A:11S-22S. doi: 10.1016/j.amjmed.2003.10.016. PMID: 15019859.
  15. Emerging Risk Factors Collaboration; Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 Jun 26;375(9733):2215-22. doi: 10.1016/S0140-6736(10)60484-9. Erratum in: Lancet. 2010 Sep 18;376(9745):958. Hillage, H L [corrected to Hillege, H L]. PMID: 20609967; PMCID: PMC2904878.
  16. Chen R, Ovbiagele B, Feng W. Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. Am J Med Sci. 2016 Apr;351(4):380-6. doi: 10.1016/j.amjms.2016.01.011. PMID: 27079344; PMCID: PMC5298897.
  17. Karapanayiotides T, Piechowski-Jozwiak B, van Melle G, Bogousslavsky J, Devuyst G. Stroke patterns, etiology, and prognosis in patients with diabetes mellitus. Neurology. 2004 May 11;62(9):1558-62. doi: 10.1212/01.wnl.0000123252.55688.05. PMID: 15136681.
  18. Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, Preckel B. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. J Clin Med. 2021 May 29;10(11):2419. doi: 10.3390/jcm10112419. PMID: 34072487; PMCID: PMC8199251.
  19. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001 Jan-Feb;15(1):44-54. doi: 10.1016/s1056-8727(00)00132-x. PMID: 11259926.
  20. Saluja M, Swami YK, Meena SR.  Study of Impact of Glycemic Status (HbA1c) on Platelet Activity measured by Mean Platelet Volume & Vascular Complications in Diabetics. J Assoc Physicians India. 2019 Apr;67(4):26-29. PMID: 31309791.
  21. Rusak T, Misztal T, Rusak M, Branska-Januszewska J, Tomasiak M. Involvement of hyperglycemia in the development of platelet procoagulant response: the role of aldose reductase and platelet swelling. Blood Coagul Fibrinolysis. 2017 Sep;28(6):443-451. doi: 10.1097/MBC.0000000000000618. PMID: 28820747.
  22. Kito K, Tanabe K, Sakata K, Fukuoka N, Nagase K, Iida M, Iida H. Endothelium-dependent vasodilation in the cerebral arterioles of rats deteriorates during acute hyperglycemia and then is restored by reducing the glucose level. J Anesth. 2018 Aug;32(4):531-538. doi: 10.1007/s00540-018-2507-7. Epub 2018 May 21. PMID: 29786114.
  23. Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep. 2007 Jun;7(3):223-7. doi: 10.1007/s11892-007-0035-1. PMID: 17547839.
  24. Lallukka S, Luukkonen PK, Zhou Y, Isokuortti E, Leivonen M, Juuti A, Hakkarainen A, Orho-Melander M, Lundbom N, Olkkonen VM, Lassila R, Yki-Järvinen H. Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans. Thromb Haemost. 2017 Jan 26;117(2):286-294. doi: 10.1160/TH16-09-0716. Epub 2016 Dec 8. PMID: 27929200.
  25. Neergaard-Petersen S, Hvas AM, Kristensen SD, Grove EL, Larsen SB, Phoenix F, Kurdee Z, Grant PJ, Ajjan RA. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. Thromb Haemost. 2014 Dec;112(6):1142-50. doi: 10.1160/TH14-05-0468. Epub 2014 Sep 4. PMID: 25187394.
  26. Kearney K, Tomlinson D, Smith K, Ajjan R. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol. 2017 Mar 9;16(1):34. doi: 10.1186/s12933-017-0515-9. PMID: 28279217; PMCID: PMC5345237.
  27. Wong ND, Zhao Y, Patel R, Patao C, Malik S, Bertoni AG, Correa A, Folsom AR, Kachroo S, Mukherjee J, Taylor H, Selvin E. Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study. Diabetes Care. 2016 May;39(5):668-76. doi: 10.2337/dc15-2439. Epub 2016 Mar 29. PMID: 27208374; PMCID: PMC4839178.
  28. Agarwal C, Bansal K, Pujani M, Singh K, Chauhan V, Rana D, Lukhmana S. Association of coagulation profile with microvascular complications and glycemic control in type 2 diabetes mellitus - a study at a tertiary care center in Delhi. Hematol Transfus Cell Ther. 2019 Jan-Mar;41(1):31-36. doi: 10.1016/j.htct.2018.05.002. Epub 2018 Jun 11. PMID: 30793102; PMCID: PMC6371197.
  29. Al Sabbah H, Alketbi M, Dghaim R. Prevalence of complications in type 2 diabetics in Dubai, UAE: a cross-sectional study. Arab J Nutr Exerc. 2019. doi 10.18502/ajne.v4i2.5161.
  30. Sulaiman N, Mahmoud I, Hussein A, Elbadawi S, Abusnana S, Zimmet P, Shaw J. Diabetes risk score in the United Arab Emirates: a screening tool for the early detection of type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2018 Mar 29;6(1):e000489. doi: 10.1136/bmjdrc-2017-000489. PMID: 29629178; PMCID: PMC5884268.
  31. Li J, Han B, Li H, Deng H, Méndez-Sánchez N, Guo X, Qi X. Association of coagulopathy with the risk of bleeding after invasive procedures in liver cirrhosis. Saudi J Gastroenterol. 2018 Jul-Aug;24(4):220-227. doi: 10.4103/sjg.SJG_486_17. PMID: 29956689; PMCID: PMC6080155.
  32. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009 Mar 26;113(13):2878-87. doi: 10.1182/blood-2008-06-165845. Epub 2008 Nov 13. PMID: 19008457.
  33. Simes J, Robledo KP, White HD, Espinoza D, Stewart RA, Sullivan DR, Zeller T, Hague W, Nestel PJ, Glasziou PP, Keech AC, Elliott J, Blankenberg S, Tonkin AM; LIPID Study Investigators. D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease: LIPID Study. Circulation. 2018 Aug 14;138(7):712-723. doi: 10.1161/CIRCULATIONAHA.117.029901. PMID: 29367425.
  34. Zhao X, Li J, Tang X, Jiang L, Chen J, Qiao S, Yang Y, Gao R, Xu B, Yuan J. D-dimer as a thrombus biomarker for predicting 2-year mortality after percutaneous coronary intervention. Ther Adv Chronic Dis. 2020 Mar 16;11:2040622320904302. doi: 10.1177/2040622320904302. PMID: 32206246; PMCID: PMC7076575.
  35. Zhou Q, Xue Y, Shen J, Zhou W, Wen Y, Luo S. Predictive values of D-dimer for the long-term prognosis of acute ST-segment elevation infarction: A retrospective study in southwestern China. Medicine (Baltimore). 2020 Apr;99(16):e19724. doi: 10.1097/MD.0000000000019724. PMID: 32311962; PMCID: PMC7220445.
  36. Cheng L, Fu Q, Zhou L, Fan Y, Liu F, Fan Y, Zhang X, Lin W, Wu X. D-dimer as a predictor of cardiovascular outcomes in patients with diabetes mellitus. BMC Cardiovasc Disord. 2022 Mar 4;22(1):82. doi: 10.1186/s12872-022-02531-x. PMID: 35246061; PMCID: PMC8895572.
  37. Lippi G, Franchini M, Targher G, Montagnana M, Salvagno GL, Guidi GC, Favaloro EJ. Epidemiological association between fasting plasma glucose and shortened APTT. Clin Biochem. 2009 Jan;42(1-2):118-20. doi: 10.1016/j.clinbiochem.2008.10.012. Epub 2008 Nov 5. PMID: 19014926.
  38. Selleh PK, Anto EO, Boadu WIO, Sackey B, Boateng LA, Nkansah C, Nsafoah F, Saasi AR, Mintaah S, Wiafe YA, Derigubah C, Korsah EE, Frimpong J, Ansah E, Tamakloe VCKT, Adu P, Boachie J, Addai-Mensah O. Quality of glycemic control in type 2 diabetes mellitus (T2DM) and its association with markers of coagulation and inhibitors of fibrinolysis: A case-control study in the Upper West Region, Ghana. Health Sci Rep. 2023 Jun 7;6(6):e1297. doi: 10.1002/hsr2.1297. PMID: 37292102; PMCID: PMC10246457.
  39. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol. 2002 Apr 8;1:1. doi: 10.1186/1475-2840-1-1. PMID: 12119059; PMCID: PMC116615.
  40. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3(6):853-76. PMID: 18200806; PMCID: PMC2350146.
  41. Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol. 2019 Jun 15;11(3):45-63. PMID: 31333808; PMCID: PMC6628012.

Download Article
Received September 24, 2024.
Accepted November 5, 2024.
©2024 International Medical Research and Development Corporation.